After SARS-COV-2 inactivated vaccine authorization for use in different countries including Egypt, investigating its immunogenicity, safety, and efficacy in preventing COVID-19 infection is highly needed. In Egypt, immunization of HCWs in isolation hospitals by SARS-COV-2 inactivated vaccine is now a national priority. Moreover, data and reports regarding the application of vaccine are still limited and deficient.
This study will be conducted at Zagazig University hospital. Laboratory work will be implemented at Immunology Research Laboratory at Microbiology and Immunology Department, Faculty of Medicine, Zagazig University. A representative sample will be drawn from healthcare workers (HCWs) at Zagazig University Hospital. Assessment of inclusion and exclusion criteria by history taking. Blood samples will be drawn from HCWs by direct venipuncture before the start of immunization and 14 days after immunization. The incidence of any adverse reactions after each immunization will be recorded. SARS-CoV-2 neutralizing antibodies will be detected by enzyme-linked immunosorbent assay.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
PREVENTION
Masking
NONE
Enrollment
246
Quantitation of SARS-Cov-2 antibody titer at baseline after each dose of the vaccine
Zagazig University Faculty of Medicine
Zagazig, Sharqia Province, Egypt
Incidence of adverse reactions
Incidence of adverse reactions after each dose of the vaccine
Time frame: 7 days after each dose
Seroconversion rate of neutralizing antibody
Neutralizing antibody assay will be performed after each dose of the vaccine
Time frame: 84 days after each dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.